GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo

OncoImmunology

Volumn 4, Issue 12, 2015, Pages

  Pedroza Gonzalez, Alexander ^a,b   Zhou, Guoying ^a   Singh, Simar Pal ^a   Boor, Patrick P C ^a   Pan, Qiuwei ^a   Grunhagen, Dirk ^a   de Jonge, Jeroen ^a   Tran, T C Khe ^a   Verhoef, Cornelis ^a   IJzermans, Jan N M ^a   Janssen, Harry L A ^a   Biermann, Katharina ^a   Kwekkeboom, Jaap ^a   Sprengers, Dave ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

cytotoxic T lymphocyte associated antigen 4 (CTLA 4); glucocorticoid induced tumor necrosis factor receptor (GITR); hepatocellular carcinoma (HCC); liver metastases from colorectal cancer (LM CRC); regulatory T cells (Treg)

Indexed keywords

CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; LIVER CANCER; LIVER CELL CARCINOMA; MALE; MYELOID DENDRITIC CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 84944578399     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1051297     Document Type: Article

References (41)

1. P.Anthony. Hepatocellular carcinoma: an overview. Histopathology 2001; 39:109-18; PMID:11493326
2. D.M.Parkin, F.Bray, J.Ferlay, P.Pisani. Estimating the world cancer burden: Globocan 2000. International journal of cancer 2001; 94:153-6; PMID:11668491
3. M.C.de Jong, S.C.Mayo, C.Pulitano, S.Lanella, D.Ribero, J.Strub, C.Hubert, J.F.Gigot, R.D.Schulick, M.A.Choti. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. Journal of Gastrointestinal Surgery 2009; 13:2141-51; PMID:19795176; http://dx.doi.org/10.1007/s11605-009-1050-0
4. M.G.House, H.Ito, M.Gönen, Y.Fong, P.J.Allen, R.P.DeMatteo, M.F.Brennan, L.H.Blumgart, W.R.Jarnagin, M.I.D'Angelica. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. Journal of the American College of Surgeons 2010; 210:744-52; PMID:20421043; http://dx.doi.org/10.1016/j.jamcollsurg.2009.12.040
5. H.B.El-Serag, J.A.Marrero, L.Rudolph, K.R.Reddy. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134:1752-63; PMID:18471552; http://dx.doi.org/10.1053/j.gastro.2008.02.090
6. N.Kemeny. Presurgical chemotherapy in patients being considered for liver resection. The Oncologist 2007; 12:825-39; PMID:17673614
7. M.C.de Jong, C.Pulitano, D.Ribero, J.Strub, G.Mentha, R.D.Schulick, M.A.Choti, L.Aldrighetti, L.Capussotti, T.M.Pawlik. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Annals of surgery 2009; 250:440; PMID:19730175
8. J.M.Llovet, S.Ricci, V.Mazzaferro, P.Hilgard, E.Gane, J.F.Blanc, A.C.de Oliveira, A.Santoro, J.L.Raoul, A.Forner. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/NEJMoa0708857
9. A.B.Siegel, S.K.Olsen, A.Magun, R.S.Brown. Sorafenib: where do we go from here? Hepatology 2010; 52:360-9; PMID:20578152; http://dx.doi.org/10.1002/hep.23633
10. A.Pedroza-Gonzalez, K.Xu, T.C.Wu, C.Aspord, S.Tindle, F.Marches, M.Gallegos, E.C.Burton, D.Savino, T.Hori et al. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 2011; 208:479-90; PMID:21339324; http://dx.doi.org/10.1084/jem.20102131
11. A.D.Pardee, L.H.Butterfield. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology 2012; 1:48-55; PMID:22720211; http://dx.doi.org/10.4161/onci.1.1.18344
12. A.Pedroza-Gonzalez, C.Verhoef, J.N.Ijzermans, M.P.Peppelenbosch, J.Kwekkeboom, J.Verheij, H.L.Janssen, D.Sprengers. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 2013; 57:183-94; PMID:22911397; http://dx.doi.org/10.1002/hep.26013
13. J.Zhou, T.Ding, W.Pan, L.Y.Zhu, L.Li, L.Zheng. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 2009; 125:1640-8; PMID:19569243; http://dx.doi.org/10.1002/ijc.24556
14. J.Fu, D.Xu, Z.Liu, M.Shi, P.Zhao, B.Fu, Z.Zhang, H.Yang, H.Zhang, C.Zhou et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132:2328-39; PMID:17570208; http://dx.doi.org/10.1053/j.gastro.2007.03.102
15. E.Unitt, S.M.Rushbrook, A.Marshall, S.Davies, P.Gibbs, L.S.Morris, N.Coleman, G.J.Alexander. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology 2005; 41:722-30; PMID:15791620; http://dx.doi.org/10.1002/hep.20644
16. A.Pedroza-Gonzalez, J.Kwekkeboom, D.Sprengers. T-cell suppression mediated by regulatory T cells infiltrating hepatic tumors can be overcome by GITRL treatment. Oncoimmunology 2013; 2:e22450; PMID:23483229; http://dx.doi.org/10.4161/onci.22450
17. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
18. J.D.Wolchok, B.Neyns, G.Linette, S.Negrier, J.Lutzky, L.Thomas, W.Waterfield, D.Schadendorf, M.Smylie, T.Guthrie, Jr. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/S1470-2045(09)70334-1
19. B.Sangro, C.Gomez-Martin, M.de la Mata, M.Inarrairaegui, E.Garralda, P.Barrera, J.I.Riezu-Boj, E.Larrea, C.Alfaro, P.Sarobe et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013; 59:81-8; PMID:23466307; http://dx.doi.org/10.1016/j.jhep.2013.02.022
20. N.Kobayashi, N.Hiraoka, W.Yamagami, H.Ojima, Y.Kanai, T.Kosuge, A.Nakajima, S.Hirohashi. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13:902-11; PMID:17289884; http://dx.doi.org/10.1158/1078-0432.CCR-06-2363
21. K.J.Chen, S.Z.Lin, L.Zhou, H.Y.Xie, W.H.Zhou, A.Taki-Eldin, S.S.Zheng. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 2011; 6:e24671; PMID:21935436
22. X.Shen, N.Li, H.Li, T.Zhang, F.Wang, Q.Li. Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. J Cancer Res Clin Oncol 2010; 136:1745-54; PMID:20221638; http://dx.doi.org/10.1007/s00432-010-0833-8
23. K.L.Ling, S.E.Pratap, G.J.Bates, B.Singh, N.J.Mortensen, B.D.George, B.F.Warren, J.Piris, G.Roncador, S.B.Fox et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun 2007; 7:7; PMID:17388261
24. K.W.Brudvik, K.Henjum, E.M.Aandahl, B.A.Bjornbeth, K.Tasken. Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer. Cancer Immunol Immunother 2012; 61:1045-53; PMID:22159472; http://dx.doi.org/10.1007/s00262-011-1174-4
25. A.Sasaki, F.Tanaka, K.Mimori, H.Inoue, S.Kai, K.Shibata, M.Ohta, S.Kitano, M.Mori. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 2008; 34:173-9; PMID:17928188; http://dx.doi.org/10.1016/j.ejso.2007.08.008
26. J.Liu, N.Zhang, Q.Li, W.Zhang, F.Ke, Q.Leng, H.Wang, J.Chen, H.Wang. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One 2011; 6:e19495; PMID:21559338
27. B.Hoechst, L.A.Ormandy, M.Ballmaier, F.Lehner, C.Kruger, M.P.Manns, T.F.Greten, F.Korangy. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135:234-43; PMID:18485901; http://dx.doi.org/10.1053/j.gastro.2008.03.020
28. E.Jones, M.Dahm-Vicker, A.K.Simon, A.Green, F.Powrie, V.Cerundolo, A.Gallimore. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002; 2:1; PMID:12747746
29. J.Dannull, Z.Su, D.Rizzieri, B.K.Yang, D.Coleman, D.Yancey, A.Zhang, P.Dahm, N.Chao, E.Gilboa et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-33; PMID:16308572; http://dx.doi.org/10.1172/JCI25947
30. T.F.Greten, L.A.Ormandy, A.Fikuart, B.Hochst, S.Henschen, M.Horning, M.P.Manns, F.Korangy. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010; 33:211-8; PMID:20139774; http://dx.doi.org/10.1097/CJI.0b013e3181bb499f
31. G.Nocentini, S.Ronchetti, M.G.Petrillo, C.Riccardi. Pharmacological modulation of GITRL/GITR system: therapeutic perspectives. Br J Pharmacol 2012; 165:2089-99; PMID:22029729; http://dx.doi.org/10.1111/j.1476-5381.2011.01753.x
32. A.D.Cohen, A.Diab, M.A.Perales, J.D.Wolchok, G.Rizzuto, T.Merghoub, D.Huggins, C.Liu, M.J.Turk, N.P.Restifo et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer research 2006; 66:4904-12; PMID:16651447; http://dx.doi.org/10.1158/0008-5472.CAN-05-2813
33. A.D.Cohen, D.A.Schaer, C.Liu, Y.Li, D.Hirschhorn-Cymmerman, S.C.Kim, A.Diab, G.Rizzuto, F.Duan, M.A.Perales et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 2010; 5:e10436; PMID:20454651
34. J.T.Murphy, A.P.Burey, A.M.Beebe, D.Gu, L.G.Presta, T.Merghoub, J.D.Wolchok. Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood 2014; 123:2172-80; PMID:24558202; http://dx.doi.org/10.1182/blood-2013-12-544742
35. K.Wing, E.Suri-Payer, A.Rudin. CD4+ CD25+-Regulatory T Cells from Mouse to Man. Scandinavian journal of immunology 2005; 62:1-15; PMID:16091121; http://dx.doi.org/10.1111/j.1365-3083.2005.01634.x
36. K.Wing, Y.Onishi, P.Prieto-Martin, T.Yamaguchi, M.Miyara, Z.Fehervari, T.Nomura, S.Sakaguchi. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322:271-5; PMID:18845758; http://dx.doi.org/10.1126/science.1160062
37. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
38. G.Q.Phan, J.C.Yang, R.M.Sherry, P.Hwu, S.L.Topalian, D.J.Schwartzentruber, N.P.Restifo, L.R.Haworth, C.A.Seipp, L.J.Freezer et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372-7; PMID:12826605
39. K.E.Beck, J.A.Blansfield, K.Q.Tran, A.L.Feldman, M.S.Hughes, R.E.Royal, U.S.Kammula, S.L.Topalian, R.M.Sherry, D.Kleiner et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24:2283-9; PMID:16710025
40. V.A.Trinh, B.Hagen. Ipilimumab for advanced melanoma: a pharmacologic perspective. J Oncol Pharm Pract 2013; 19:195-201; PMID:23047236
41. S.K.Pruitt, D.Boczkowski, N.de Rosa, N.R.Haley, M.A.Morse, D.S.Tyler, J.Dannull, S.Nair. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol 2011; 41:3553-63.; PMID:22028176